[Form 4] Kineta, Inc. Common Stock Insider Trading Activity

Rhea-AI Filing Summary

Leidos Holdings, Inc. (LDOS) – Form 4 insider transaction

Chief Financial Officer Christopher R. Cage reported one transaction dated 06/30/2025.

• Acquisition: 64.1944 shares of common stock credited at $0.00 per share. The shares represent dividend-equivalent rights that were automatically reinvested in the company’s Key Executive Stock Deferral Plan.
• Post-transaction ownership: 29,288.682 indirect shares held via the deferral plan and 46,953 direct shares.

No derivative securities were involved and no sales were disclosed. The filing does not indicate any open-market purchases or dispositions; the recorded activity is routine and non-cash. Given the immaterial share amount relative to the executive’s existing holdings, the filing is unlikely to have a meaningful impact on LDOS’s share count or market perception.

Insights

Securities Analyst

TL;DR: Routine dividend-equivalent share accrual; negligible market impact.

The CFO’s acquisition of 64 shares at no cost is a standard bookkeeping entry tied to deferred compensation. After the credit, his indirect holdings total roughly 29.3k shares, while direct ownership remains 46.9k shares. There is no evidence of discretionary buying or selling, and the transaction neither signals bullish nor bearish sentiment. Investors can treat the filing as administratively neutral.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PHILIPS CRAIG W.

(Last) (First) (Middle)

C/O TUHURA BIOSCIENCES, INC.

10500 UNIVERSITY CENTER DRIVE, SUITE 110

(Street)

TAMPA FL 33612

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KINETA, INC./DE [ KANT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and Secretary

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2025		D(1)(2)		298,464	D	(3)	0	D
Common Stock	06/30/2025		D(1)(2)		34,654	D	(3)	0	I	By Whetstone Ventures, LLC(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.28	06/30/2025		D(1)(2)			44,310	(5)	(5)	Common Stock	44,310	$0	0	D
Stock Option (Right to Buy)	$3.28	06/30/2025		D(1)(2)			121,290	(5)	(5)	Common Stock	121,290	$0	0	D
Stock Option (Right to Buy)	$27.03	06/30/2025		D(1)(2)			3,698	(5)	(5)	Common Stock	3,698	$0	0	D
Stock Option (Right to Buy)	$27.03	06/30/2025		D(1)(2)			15,221	(5)	(5)	Common Stock	15,221	$0	0	D
Stock Option (Right to Buy)	$26.16	06/30/2025		D(1)(2)			51,600	(5)	(5)	Common Stock	51,600	$0	0	D
Stock Option (Right to Buy)	$29.06	06/30/2025		D(1)(2)			6,897	(5)	(5)	Common Stock	6,897	$0	0	D
Stock Option (Right to Buy)	$29.06	06/30/2025		D(1)(2)			10,302	(5)	(5)	Common Stock	10,302	$0	0	D
Stock Option (Right to Buy)	$23.25	06/30/2025		D(1)(2)			63	(5)	(5)	Common Stock	63	$0	0	D
Stock Option (Right to Buy)	$23.25	06/30/2025		D(1)(2)			1,742	(5)	(5)	Common Stock	1,742	$0	0	D
Stock Option (Right to Buy)	$23.25	06/30/2025		D(1)(2)			3,440	(5)	(5)	Common Stock	3,440	$0	0	D
Stock Option (Right to Buy)	$23.25	06/30/2025		D(1)(2)			29,842	(5)	(5)	Common Stock	29,842	$0	0	D
Stock Option (Right to Buy)	$23.25	06/30/2025		D(1)(2)			3,440	(5)	(5)	Common Stock	3,440	$0	0	D
Stock Option (Right to Buy)	$23.11	06/30/2025		D(1)(2)			13,760	(5)	(5)	Common Stock	13,760	$0	0	D

Explanation of Responses:

1. This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement").

2. This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA.

3. At the effective time of the First Merger (the "Effective Time"), each one (1) issued and outstanding share of Kineta's common stock, par value $0.001 per share ("Kineta Common Stock"), was cancelled and converted into the right to receive 0.185298 share of common stock of TuHURA, par value $0.001 per share ("TuHURA Common Stock"). Also pursuant to the Merger Agreement, each one (1) share of Kineta Common Stock is also entitled to (i) its pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses incurred or accrued during the six month period from the closing of the Mergers, and (ii) the right to its pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets.

4. The Reporting Person is a member manager of Whetstone Ventures, LLC ("Whetstone") and shares voting and dispositive power over the shares held by Whetstone.

5. At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration.

	/s/ Albert W. Vanderlaan, as Attorney-in-Fact	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.